Pharma BD Deal Intelligence
Less than 30 months after Idrx emerged from stealth mode, GSK is acquiring the private start-up for $1 billion up front to gain its sole clinical asset: a…
GSK acquires IDRx for $1B hoping to bring GIST patients new standard of care with IDRX-42.
In these spaces, Walmsley highlighted the company's recent acquisition of IDRx as an example of what the pharma is looking for in the coming year. Announced…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
GSK plc acquired clinical-stage oncology company IDRx, Inc. for up to $1.15 billion ($1.0 billion upfront plus a $150 million success-based regulatory milestone), announced January 13, 2025 and completed February 24, 2025. The deal centers on IDRX-42 (GSK6042981; proposed INN velzatinib), a highly selective, broad-spectrum KIT tyrosine kinase inhibitor designed to cover both primary and secondary KIT mutations in gastrointestinal stromal tumors (GIST) — the resistance gap that limits existing TKIs, where ~90% of first-line patients develop resistant mutations. IDRX-42 holds FDA Fast Track and Orphan Drug designations; GSK is also responsible for milestones and tiered royalties owed to Merck KGaA. Following close, GSK advanced the asset into the Phase 3 StrateGIST 3 trial (NCT07218926), evaluating IDRX-42 versus sunitinib in second-line GIST after imatinib with progression-free survival as the primary endpoint (recruiting since December 2025), alongside an ongoing first-line Phase 3 program.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / IDRx Inc. (this deal) | 2025 | $1.1B | 66 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2025 deals · GSK plc deals · Oncology deals